Acromegaly – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acromegaly – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ALXN2420 with somatostatin analogs for adults with acromegaly to evaluate effectiveness in lowering IGF-1 levels https://clinicaltrials.eu/trial/study-of-alxn2420-with-somatostatin-analogs-for-adults-with-acromegaly-to-evaluate-effectiveness-in-lowering-igf-1-levels/ Thu, 30 Apr 2026 13:08:03 +0000 https://clinicaltrials.eu/trial/study-of-alxn2420-with-somatostatin-analogs-for-adults-with-acromegaly-to-evaluate-effectiveness-in-lowering-igf-1-levels/ This study focuses on people with Acromegaly, a condition caused by a tumor in the pituitary gland that produces excess growth hormone. The research evaluates a new medication called ALXN2420 used together with existing treatments called somatostatin analogs (octreotide acetate or lanreotide acetate). These medications help control the excessive hormone production that causes the symptoms of acromegaly.

The purpose of this study is to determine if ALXN2420 can help lower levels of a hormone called IGF-1 in people with acromegaly when combined with standard treatments. The study compares ALXN2420 to placebo, with both being given alongside regular acromegaly medications. The treatment period lasts for 15 weeks, during which participants receive either ALXN2420 or placebo through injections under the skin.

Throughout the study, participants continue their regular acromegaly medications, which are given as injections either into the muscle or under the skin once every four weeks. The study monitors how well the combination of treatments works by measuring hormone levels and tracking any changes in symptoms. Participants also complete questionnaires about their quality of life and overall health during the study period.

]]> Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs https://clinicaltrials.eu/trial/study-of-debio-4126-a-new-octreotide-formulation-compared-to-placebo-in-patients-with-acromegaly-who-were-previously-treated-with-somatostatin-analogs/ Wed, 29 Apr 2026 15:06:22 +0000 https://clinicaltrials.eu/trial/study-of-debio-4126-a-new-octreotide-formulation-compared-to-placebo-in-patients-with-acromegaly-who-were-previously-treated-with-somatostatin-analogs/ This clinical trial focuses on patients with acromegaly, a condition where the body produces too much growth hormone. The study evaluates a new medication called Debio 4126, which is a 12-week formulation of octreotide, compared to a placebo and other treatments. The purpose is to determine if Debio 4126 can effectively maintain normal levels of insulin-like growth factor 1 (IGF-1) in patients who have previously been treated with medications called somatostatin analogs.

The study involves three groups of participants. Some patients will receive Debio 4126 through intramuscular injection, while others will receive a placebo. The third group will receive Debio 4126 in an open-label manner, meaning both the doctor and patient know which treatment is being given. The medication will be administered every 12 weeks, and patients will be monitored for changes in their IGF-1 levels and overall health throughout the study period.

The treatment may also include other medications such as lanreotide for some participants. Throughout the study, doctors will monitor the safety of the treatment by checking various health parameters, including blood tests, vital signs, and the size of the pituitary tumor. They will also evaluate how well patients tolerate the injections by assessing any reactions at the injection site.

]]> Study on the Effects of Pegvisomant and Somatropin on Liver Fat Metabolism in Patients with Acromegaly and Healthy Individuals https://clinicaltrials.eu/trial/study-on-the-effects-of-pegvisomant-and-somatropin-on-liver-fat-metabolism-in-patients-with-acromegaly-and-healthy-individuals/ Wed, 29 Apr 2026 15:05:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-pegvisomant-and-somatropin-on-liver-fat-metabolism-in-patients-with-acromegaly-and-healthy-individuals/ This clinical trial is focused on studying the effects of growth hormone on liver fat metabolism in humans. The study involves two groups of participants: those with acromegaly, a condition where the body produces too much growth hormone, and healthy individuals. The treatment being tested includes two medications: SOMAVERT, which contains the active substance pegvisomant, and Genotropin, which contains somatropin. Both medications are administered as a solution for injection under the skin.

The purpose of the study is to understand how growth hormone affects the liver’s ability to process fats and energy. Participants will receive either the medication or a placebo, and the study will observe changes in the body’s energy use, liver fat content, and the production of certain types of fat in the liver. The study will also look at how these changes affect overall body composition and energy expenditure.

Participants will be involved in the study for a short period, during which they will receive injections and undergo various assessments to monitor the effects of the treatment. The study aims to provide insights into how growth hormone influences liver function and fat metabolism, which could have implications for treating conditions related to growth hormone levels.

]]> Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly https://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-efficacy-of-paltusotine-for-patients-with-acromegaly/ Wed, 29 Apr 2026 15:01:30 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-and-efficacy-of-paltusotine-for-patients-with-acromegaly/ This clinical trial is focused on studying the condition known as acromegaly, a disorder that results from the body producing too much growth hormone, leading to enlarged bones and tissues. The treatment being tested in this study is a medication called paltusotine, which is taken in the form of tablets. Paltusotine is also known by its code name, CRN00808.

The purpose of this study is to evaluate the long-term safety and effectiveness of paltusotine in individuals with acromegaly. Participants in the study will take paltusotine tablets orally. The study will monitor the safety of the medication by observing any side effects that occur during the trial. Additionally, the study will assess how well paltusotine works by measuring changes in levels of certain hormones, such as insulin-like growth factor 1 (IGF-1) and growth hormone (GH), which are typically elevated in acromegaly.

This study is an open-label, long-term extension, meaning that all participants will know they are receiving paltusotine, and the study will continue for an extended period to gather comprehensive data on the medication’s effects. The trial aims to provide valuable insights into the management of acromegaly with paltusotine, potentially offering a new treatment option for those affected by this condition.

]]> Study on the Safety and Effectiveness of Paltusotine for Patients with Acromegaly https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-paltusotine-for-patients-with-acromegaly/ Wed, 29 Apr 2026 14:59:37 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-paltusotine-for-patients-with-acromegaly/ This clinical trial is focused on studying the condition known as acromegaly, a disorder that results from the body producing too much growth hormone, leading to enlarged bones and other tissues. The study will evaluate the safety and effectiveness of a new treatment called paltusotine, which is taken in tablet form. Paltusotine is being compared to a placebo to understand its impact on the levels of a protein called IGF-1, which is often elevated in people with acromegaly.

The purpose of the study is to assess how well paltusotine works in managing acromegaly symptoms and maintaining normal IGF-1 levels. Participants in the study will be randomly assigned to receive either paltusotine or a placebo. The study will involve regular check-ups and monitoring over a period of time to observe any changes in the condition and to ensure the safety of the participants. The study will also look at changes in symptoms and other health markers related to acromegaly.

Throughout the study, participants will continue to receive care and support from the study team. The trial aims to provide valuable information on whether paltusotine can be a safe and effective treatment option for people living with acromegaly. This research is important for developing new ways to manage this condition and improve the quality of life for those affected.

]]> Study on the Effects of Paltusotine for Patients with Untreated Acromegaly https://clinicaltrials.eu/trial/study-on-the-effects-of-paltusotine-for-patients-with-untreated-acromegaly/ Wed, 29 Apr 2026 14:59:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-paltusotine-for-patients-with-untreated-acromegaly/ This clinical trial is focused on studying a condition called acromegaly. Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone, leading to enlarged bones and tissues. The study will test a medication called paltusotine, which is taken in tablet form. Paltusotine is being compared to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well paltusotine works in managing acromegaly in patients who have not been treated with medication for this condition. Participants in the study will be randomly assigned to receive either paltusotine or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will take the assigned tablets and attend regular check-ups to monitor their health and the effects of the treatment. The study aims to see if paltusotine can help control the levels of a substance called IGF-1 in the body, which is often elevated in people with acromegaly. The trial will also assess any changes in symptoms related to acromegaly and overall well-being. The study is expected to continue until 2027, providing valuable information on the safety and effectiveness of paltusotine for treating acromegaly.

]]> Study of long-term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-octreotide-hydrochloride-for-patients-with-acromegaly/ Wed, 29 Apr 2026 14:30:07 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-octreotide-hydrochloride-for-patients-with-acromegaly/ This clinical trial focuses on patients with acromegaly, a condition where the body produces too much growth hormone, leading to abnormal growth of body tissues. The study tests a medication called CAM2029, which contains octreotide and is given as an injection under the skin. This new form of the medication is being developed to help control acromegaly symptoms over a long period.

The main purpose of this study is to evaluate how safe and well-tolerated CAM2029 is when used long-term in people with acromegaly. The medication is administered as a subcutaneous injection, which means it is given under the skin. The study consists of two parts: a main part lasting 52 weeks, followed by an extension period for additional long-term observation.

During the study, participants receive regular doses of CAM2029. The treatment can be given at doses up to 20 mg per day, with the total amount over the study period not exceeding 520 mg. Throughout the study, doctors monitor various aspects of participants’ health, including how well their acromegaly symptoms are controlled and their overall well-being.

]]>